Grapow Martin T R, Carrel Thierry P, Eckstein Friedrich S
Klinik fur Herzchirurgie, Universitatsspital Basel, Spitalstrasse 10, Basel-Bern.
Ther Umsch. 2011 Feb;68(2):95-102. doi: 10.1024/0040-5930/a000126.
Despite significant improvements in pharmacological therapy heart failure is still one of the leading causes for death in the Western World. The gold standard treatment of end-stage heart failure remains cardiac transplantation, but there is a great excess of eligible candidates compared with the low number of suitable donor organs. The variety of surgical organ preserving treatment strategies has significantly increased during the last 20 years, intenting either to delay or even to prevent the need for cardiac transplantation. An individually tailored surgical concept should be considered as an alternative in any heart failure patient who has reached the limits of pharmacologic therapy. This article gives an overview about current and potential future therapeutic options in end-stage heart failure.
尽管药物治疗有了显著改善,但心力衰竭仍是西方世界主要的死亡原因之一。终末期心力衰竭的金标准治疗仍然是心脏移植,但合格的候选者数量远远超过合适的供体器官数量。在过去20年中,各种手术性器官保留治疗策略显著增加,目的是延缓甚至预防心脏移植的需求。对于任何已达到药物治疗极限的心力衰竭患者,应考虑采用个体化定制的手术方案作为替代方案。本文概述了终末期心力衰竭当前及未来可能的治疗选择。